Sectors

INCY
Incyte Corporation
116.66
1 x 116.76
2 x 116.84
bid
ask
-
0.73
0.62%
01:42 PM
timesize
Ytd18.11%
1y69.32%
116.27
day range
118.66
68.90
52 week range
118.52
Open116.27Prev Close117.39Low116.27High118.66Mkt Cap23.45B
Vol369.47KAvg Vol1.74MEPS7.44P/E15.78Forward P/E15.06
Beta0.76Short Ratio4.72Inst. Own106.64%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning07-2850-d Avg105.37200-d Avg99.851yr Est113.82

INCY News

HALO Inks Deal With INCY to Support Cancer Therapy Development
zacks.com
HALO Inks Deal With INCY to Support Cancer Therapy Development

Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, ai

Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
zacks.com
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat

benzinga.com
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $140 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

Bank of New York Mellon Corp Trims Stock Position in Incyte Corporation $INCY
defenseworld.net
Bank of New York Mellon Corp Trims Stock Position in Incyte Corporation $INCY

Bank of New York Mellon Corp lessened its holdings in Incyte Corporation (NASDAQ: INCY) by 1.3% duri

Fifth Third Bancorp Boosts Stock Position in Incyte Corporation $INCY
defenseworld.net
Fifth Third Bancorp Boosts Stock Position in Incyte Corporation $INCY

Fifth Third Bancorp boosted its stake in shares of Incyte Corporation (NASDAQ: INCY) by 145.2% in th

Andra AP fonden Has $24.38 Million Holdings in Incyte Corporation $INCY
defenseworld.net
Andra AP fonden Has $24.38 Million Holdings in Incyte Corporation $INCY

Andra AP fonden lessened its position in Incyte Corporation (NASDAQ: INCY) by 34.6% during the undef

benzinga.com
Halozyme Therapeutics Signs Agreement With Incyte To Mull Additional Subcutaneous Formulations Of IN

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
prnewswire.com
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development

Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR developm

benzinga.com
Incyte To Present New Phase 1 Solid Tumor Data, Including KRAS G12D and TGFβR2×PD‑1 Programs, At ESM

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth I

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
businesswire.com
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical O

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Data to Be Highlighted in Four Rapid Oral Presen

benzinga.com
Barclays Maintains Overweight on Incyte, Raises Price Target to $134

Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the pri

Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder
benzinga.com
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood D

Incyte reports Phase 1/2 latarcibart data showing lower bleeding rates and favorable safety in patie

benzinga.com
BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $112

BMO Capital analyst Evan Seigerman maintains Incyte (NASDAQ:INCY) with a Market Perform and raise

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
gurufocus.com
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial

Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enr

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
businesswire.com
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Phase 1/2 Multidose Data for VGA039 (Latarcibart) Show

2 Fast-Growing Pharmaceutical Stocks to Buy Now
fool.com
2 Fast-Growing Pharmaceutical Stocks to Buy Now

Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings

Incyte to Report Second Quarter Financial Results
businesswire.com
Incyte to Report Second Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its se

benzinga.com
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $99

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raise

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
businesswire.com
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, E

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Completes Acquisition of Vega Therapeutics, a Wh

Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion
fxempire.com
Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion

Three outlier inflow signals push biopharmaceutical firm Incyte Corporation (INCY) up 71% in a year.

INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
zacks.com
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura

Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS

Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
zacks.com
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?

Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average

Incyte: New Catalysts Support Another Leg Higher
seekingalpha.com
Incyte: New Catalysts Support Another Leg Higher

Incyte Corporation remains a strong long pick, with a maintained 'Buy' rating and a 40% upside to a

benzinga.com
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $140 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

benzinga.com
UBS Maintains Neutral on Incyte, Raises Price Target to $113

UBS analyst Ashwani Verma maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price targ

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
gurufocus.com
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP)

benzinga.com
Incyte Announces EMA CHMP Positive Opinion Recommending Approval Of Opzelura Cream For Moderate Atop

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment opt

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
businesswire.com
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults

MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Opzelura®

benzinga.com
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $140 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

benzinga.com
Truist Securities Maintains Hold on Incyte, Raises Price Target to $105

Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:INCY) with a Hold and rai

Micron To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday
benzinga.com
Micron To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed outlook on top names. See all changes, including upgrades/downgrade

This ConocoPhillips Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
benzinga.com
This ConocoPhillips Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts upgraded APA, INCY, COP, OVV, BWXT stocks with higher price targets. Check

Here Are Monday's Best Wall Street Analyst Research Calls: Accenture, Apple, Boyd Gaming, BWX Technologies, Conoco-Phillips, Estee Lauder, Hut 8, Incyte, SpaceX, and More
247wallst.com
Here Are Monday's Best Wall Street Analyst Research Calls: Accenture, Apple, Boyd Gaming, BWX Techno

Futures are trading mixed as we prepare to finish the last full week of the second quarter.

benzinga.com
BMO Capital Upgrades Incyte to Market Perform, Raises Price Target to $94

BMO Capital analyst Evan Seigerman upgrades Incyte (NASDAQ:INCY) from Underperform to Market Perf

Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
zacks.com
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Earnings Scheduled For April 28, 2026
benzinga.com
Earnings Scheduled For April 28, 2026

benzinga.com
Adagene Collaborates With Incyte To Evaluate Combination Of Muzastotug And INCA33890 In Patients Wit

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and

Earnings Scheduled For February 10, 2026
benzinga.com
Earnings Scheduled For February 10, 2026

This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
benzinga.com
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday

Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday?
benzinga.com
Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday?

Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump

Earnings Scheduled For October 28, 2025
benzinga.com
Earnings Scheduled For October 28, 2025

Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday
benzinga.com
Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday

benzinga.com
Earnings Scheduled For July 29, 2025

XPeng, Reddit And Micron Tech Are Among Top 10 Large-Cap Losers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
benzinga.com
XPeng, Reddit And Micron Tech Are Among Top 10 Large-Cap Losers Last Week (Mar 17-Mar 21): Are The O

Large-cap stocks worst performers last week, including BEKE, RDDT, FUTU, JHX, INCY, NUE, BAH, XPEV,

benzinga.com
Earnings Scheduled For February 10, 2025

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  On Monday, 369 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  On Thursday, 148 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  Thursday's session saw 189 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

Stocks That Hit 52-Week Lows On Wednesday

benzinga.com
Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Monday